Answer
Sep 01, 2026 - 01:13 PM
Evorel Conti is a combined HRT patch containing estradiol and norethisterone. For many people the benefits outweigh the risks, but there are some important risks to consider.
The main longer-term concern is a small increase in breast cancer risk with combined HRT, and that risk generally increases the longer it is used. NHS estimates suggest about 5 additional cases of breast cancer per 1,000 women using combined HRT for 5 years.
Other possible risks include blood clots, stroke, and certain hormone-sensitive cancers. However, because Evorel Conti delivers estrogen through the skin, patches are generally associated with less blood-clot and stroke risk than oral HRT tablets.
More common side effects can include breast tenderness, headaches, nausea, mood changes, bloating, skin irritation where the patch is applied, and spotting or irregular bleeding, particularly during the first few months.
Evorel Conti may not be appropriate for someone with a history of breast or estrogen-sensitive cancer, unexplained xxxx bleeding, previous blood clots, stroke or heart attack, or certain liver problems.
The risks should be reviewed periodically with a healthcare professional, with HRT generally used at the lowest effective dose for as long as it continues to provide worthwhile benefits.
